TheravaxHSV is a therapeutic vaccination series. By retraining the immune system to better control herpes simplex virus (HSV), TheravaxHSV offers sufferers the possibility of reducing their genital herpes symptoms.
Phase 1 Clinical Trials of TheravaxHSV are imminent.Learn more
ProfavaxHSV is a prophylactic vaccination series that offers the opportunity for recipients to acquire protective immunity against HSV-1 or HSV-2, and thus protect themselves against the risk of acquiring oral or genital herpes.
Phase 1 Clinical Trials of ProfavaxHSV will begin after the TheravaxHSV vaccine has completed Phase 1 safety trials.Learn more
RVx has developed a new herpes serology test that measures Antibody Binding to Virus-Infected Cells (ABVIC). The HSV ABVIC Test measures a person’s total level of HSV-1 vs. HSV-2-specific antibodies in a manner that is up to 100 times more sensitive than ELISA-based tests, which represent the current standard of medical care.Learn More
…four billion people around the globe are infected with herpes simplex virus serotype 1 (HSV-1) and/or herpes simplex virus serotype 2 (HSV-2), and every week more than one million people are newly infected.